Tag Archives: Avycaz

EMBLAVEO (AZTREONAM+AVIBACTAM) Microbiology Testing for MDR Pathogens

Posted on by — No Comments ↓

The discussion emphasizes challenges in clinical antibiotic trials which failed to effectively target multi-drug resistant (MDR) pathogens. It advocates for using rapid PCR diagnostics to streamline trials, ensuring focus on pathogens of concern, and calls for regulatory adaptations to enhance study design and antibiotic testing efficacy. Continue reading EMBLAVEO (AZTREONAM+AVIBACTAM) Microbiology Testing for MDR Pathogens→

An Intro to Emblaveo (aztreonam + avibactam)

Posted on by — No Comments ↓

The FDA web site usually provides label and review documents for approved drugs.[1]  Emblaveo, the combination of aztreonam and avibactam, was approved in February 2025, almost ½ year ago, but clinical review documents are still not posted at the site.[2]  Hence, we do not know how Regulators felt about the Continue reading An Intro to Emblaveo (aztreonam + avibactam)→

The 10 x ’20 Initiative – A Retrospective

Posted on by — No Comments ↓

It started all so well with fanfare and great expectations. Fifteen years ago, the 10 x ’20 initiative got underway. Its goals were spelled out clearly: To ‘Pursue a Global Commitment to Develop 10 New Antibacterial Drugs by 2020 ’[3].  It was driven by ID clinicians and by antibiotic developers concerned Continue reading The 10 x ’20 Initiative – A Retrospective→